» Articles » PMID: 33875435

Developing Cyclic Peptomers As Broad-Spectrum Type III Secretion System Inhibitors in Gram-Negative Bacteria

Overview
Specialty Pharmacology
Date 2021 Apr 20
PMID 33875435
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Antibiotic-resistant bacteria are an emerging global health threat. New antimicrobials are urgently needed. The injectisome type III secretion system (T3SS), required by dozens of Gram-negative bacteria for virulence but largely absent from nonpathogenic bacteria, is an attractive antimicrobial target. We previously identified synthetic cyclic peptomers, inspired by the natural product phepropeptin D, that inhibit protein secretion through the Ysc and Pseudomonas aeruginosa Psc T3SSs but do not inhibit bacterial growth. Here, we describe the identification of an isomer, 4EpDN, that is 2-fold more potent (50% inhibitory concentration [IC] of 4 μM) than its parental compound. Furthermore, 4EpDN inhibited the Ysa and the Salmonella SPI-1 T3SSs, suggesting that this cyclic peptomer has broad efficacy against evolutionarily distant injectisome T3SSs. Indeed, 4EpDN strongly inhibited intracellular growth of Chlamydia trachomatis in HeLa cells, which requires the T3SS. 4EpDN did not inhibit the unrelated twin arginine translocation (Tat) system, nor did it impact T3SS gene transcription. Moreover, although the injectisome and flagellar T3SSs are evolutionarily and structurally related, the 4EpDN cyclic peptomer did not inhibit secretion of substrates through the Salmonella flagellar T3SS, indicating that cyclic peptomers broadly but specifically target the injectisome T3SS. 4EpDN reduced the number of T3SS needles detected on the surface of Yersinia pseudotuberculosis as detected by microscopy. Collectively, these data suggest that cyclic peptomers specifically inhibit the injectisome T3SS from a variety of Gram-negative bacteria, possibly by preventing complete T3SS assembly.

Citing Articles

Chlamydial and Gonococcal Genital Infections: A Narrative Review.

Rodrigues R, Vieira-Baptista P, Catalao C, Borrego M, Sousa C, Vale N J Pers Med. 2023; 13(7).

PMID: 37511783 PMC: 10381338. DOI: 10.3390/jpm13071170.


Mixture-Based Screening of Focused Combinatorial Libraries by NMR: Application to the Antiapoptotic Protein hMcl-1.

Alboreggia G, Udompholkul P, Baggio C, Pellecchia M J Med Chem. 2023; 66(14):10108-10118.

PMID: 37464766 PMC: 10388297. DOI: 10.1021/acs.jmedchem.3c01073.


Type III Secretion in .

Rucks E Microbiol Mol Biol Rev. 2023; 87(3):e0003423.

PMID: 37358451 PMC: 10521360. DOI: 10.1128/mmbr.00034-23.


Targeting bacterial pathogenesis by inhibiting virulence-associated Type III and Type IV secretion systems.

Blasey N, Rehrmann D, Riebisch A, Muhlen S Front Cell Infect Microbiol. 2023; 12:1065561.

PMID: 36704108 PMC: 9872159. DOI: 10.3389/fcimb.2022.1065561.


Research Progress on Small Molecular Inhibitors of the Type 3 Secretion System.

Lv C, Li Y, Wei Y, Wang J, Yu H, Gao F Molecules. 2022; 27(23).

PMID: 36500441 PMC: 9740592. DOI: 10.3390/molecules27238348.


References
1.
Lee P, Rietsch A . Fueling type III secretion. Trends Microbiol. 2015; 23(5):296-300. PMC: 4417389. DOI: 10.1016/j.tim.2015.01.012. View

2.
Nordfelth R, Kauppi A, Norberg H, Wolf-Watz H, Elofsson M . Small-molecule inhibitors specifically targeting type III secretion. Infect Immun. 2005; 73(5):3104-14. PMC: 1087345. DOI: 10.1128/IAI.73.5.3104-3114.2005. View

3.
McGovern S, Helfand B, Feng B, Shoichet B . A specific mechanism of nonspecific inhibition. J Med Chem. 2003; 46(20):4265-72. DOI: 10.1021/jm030266r. View

4.
Grishin A, Luyksaar S, Kapotina L, Kirsanov D, Zayakin E, Karyagina A . Identification of chlamydial T3SS inhibitors through virtual screening against T3SS ATPase. Chem Biol Drug Des. 2017; 91(3):717-727. DOI: 10.1111/cbdd.13130. View

5.
Santajit S, Indrawattana N . Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. Biomed Res Int. 2016; 2016:2475067. PMC: 4871955. DOI: 10.1155/2016/2475067. View